OMEPRAZOLE (omeprazole) by Novartis is proton pump inhibitors [moa]. Approved for proton pump inhibitor [epc]. First approved in 2003.
Drug data last refreshed 19h ago
Proton Pump Inhibitors
Proton Pump Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55
Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal
A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants
Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants
Worked on OMEPRAZOLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.